Bures sur Yvette, France

Vincent Thuillier


 

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 9(Granted Patents)


Location History:

  • Paris, FR (2000)
  • Bures sur Yvette, FR (2007 - 2021)

Company Filing History:


Years Active: 2000-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: **Vincent Thuillier: Innovating Cancer Treatment Predictions**

Introduction

Vincent Thuillier is a prominent inventor based in Bures sur Yvette, France. With a total of four patents to his name, Thuillier has made significant contributions to the field of medical research, particularly in cancer treatment. His innovative approaches focus on improving patient outcomes by utilizing biomarkers.

Latest Patents

Among his most recent patents is a noteworthy development in predicting treatment outcomes for patients treated with aflibercept, a medication often used in cancer therapy. The invention specifically highlights the use of interleukin-8 (IL-8) as a biomarker. This research aims to enhance the accuracy of predictions for patients suspected of having cancer, making treatment more personalized and effective. Additionally, one of his patents delves into an IL-8 level-based method specifically targeting the prediction of treatment outcomes for colon cancer, showcasing his focus on gastrointestinal oncology.

Career Highlights

Thuillier has worked with esteemed pharmaceutical companies such as Aventis Pharma and Sanofi, where he honed his expertise in drug development and biomarker research. His career reflects a commitment to enhancing cancer treatment methodologies through innovative thinking and application of scientific research.

Collaborations

Throughout his career, Thuillier has collaborated with remarkable professionals in the field, including Marielle Chiron-Blondel and Diether Lambrechts. These partnerships underline the importance of teamwork in advancing medical research and developing new therapeutic strategies.

Conclusion

Vincent Thuillier stands out as an inventive force in the realm of cancer treatment. His patents, particularly those involving interleukin-8 as a predictive biomarker, demonstrate his dedication to improving patient outcomes. With his career rooted in valuable industry experience and collaborative efforts, Thuillier continues to navigate the forefront of medical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…